We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
Cap. Flow
-$803K
Cap. Flow %
-0.33%
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11

Top Buys

Rank Stock Value
1
BKCC
BlackRock Capital Investment Corporation
BKCC
+$673K
2
ZLAB icon
Zai Lab
ZLAB
+$472K
3
SCM icon
Stellus Capital Investment Corp
SCM
+$422K
4
DRD
DRDGold
DRD
+$415K
5
OXLC
Oxford Lane Capital
OXLC
+$359K

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$1.16M
2
RUBY
Rubius Therapeutics, Inc
RUBY
+$664K
3
BNTX icon
BioNTech
BNTX
+$663K
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$645K
5
PRTA icon
Prothena Corp
PRTA
+$590K

Sector Composition

Rank Sector Weight
1 Healthcare 27.38%
2 Real Estate 18.81%
3 Energy 13.29%
4 Materials 10.7%
5 Utilities 10.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MAIN icon
176
Main Street Capital
MAIN
$4.97B
$462K 0.19%
11,253
+558
+5% +$23.2K
ENTA icon
177
Enanta Pharmaceuticals
ENTA
$372M
$461K 0.19%
10,483
-4,238
-29% -$208K
DCF
178
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
$458K 0.19%
47,671
+11,054
+30% +$105K
KNSA icon
179
Kiniksa Pharmaceuticals
KNSA
$4.83B
$456K 0.19%
32,762
+17,348
+113% +$264K
BLW icon
180
BlackRock Limited Duration Income Trust
BLW
$491M
$451K 0.19%
26,496
+7,232
+38% +$122K
SRPT icon
181
Sarepta Therapeutics
SRPT
$1.66B
$451K 0.19%
5,798
+2,112
+57% +$160K
FOLD
182
DELISTED
Amicus Therapeutics
FOLD
$449K 0.18%
46,576
+20,375
+78% +$199K
ACAD icon
183
Acadia Pharmaceuticals
ACAD
$4.25B
$447K 0.18%
18,330
+6,326
+53% +$143K
HRMY icon
184
Harmony Biosciences
HRMY
$2.04B
$440K 0.18%
15,603
+281
+2% +$8.43K
GBT
185
DELISTED
Global Blood Therapeutics, Inc.
GBT
$434K 0.18%
12,396
-2,258
-15% -$88.2K
BIIB icon
186
Biogen
BIIB
$29.9B
$426K 0.18%
1,229
-1,321
-52% -$400K
EVF
187
Eaton Vance Senior Income Trust
EVF
$90.3M
$422K 0.17%
62,116
+19,923
+47% +$134K
CERE
188
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$422K 0.17%
+16,484
New +$236K
OCSL icon
189
Oaktree Specialty Lending
OCSL
$1.03B
$417K 0.17%
20,794
-7,753
-27% -$155K
NTLA icon
190
Intellia Therapeutics
NTLA
$1.5B
$412K 0.17%
2,542
-3,219
-56% -$251K
ESPR
191
DELISTED
Esperion Therapeutics
ESPR
$410K 0.17%
19,398
-1,759
-8% -$42.4K
EXEL icon
192
Exelixis
EXEL
$13.9B
$400K 0.16%
21,937
-8,495
-28% -$198K
BRW
193
Saba Capital Income & Opportunities Fund
BRW
$336M
$393K 0.16%
41,739
+12,016
+40% +$111K
SAGE
194
DELISTED
Sage Therapeutics
SAGE
$389K 0.16%
6,853
-1,999
-23% -$141K
TBPH icon
195
Theravance Biopharma
TBPH
$874M
$387K 0.16%
26,643
-6,228
-19% -$117K
FCRD
196
DELISTED
First Eagle Alternative Capital BDC, Inc. Common Stock
FCRD
$337K 0.14%
73,954
+16,172
+28% +$71.5K
MRCC
197
DELISTED
Monroe Capital Corp
MRCC
$332K 0.14%
30,911
+5,996
+24% +$64.9K
OXSQ icon
198
Oxford Square Capital
OXSQ
$151M
$330K 0.14%
67,197
+6,541
+11% +$32.4K
SUNS
199
DELISTED
SLR Senior Investment Corp. Common Stock
SUNS
$330K 0.14%
21,707
+6,188
+40% +$96K
EDIT icon
200
Editas Medicine
EDIT
$399M
$329K 0.14%
5,806
+922
+19% +$34.1K
6 7
8
9 10

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2021 Portfolio in Review

As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.

Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.

  • Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
  • Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
  • Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
  • Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
  • Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
  • Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
  • Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.

Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.